Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
remdesivir - versus potential COVID-19 treatments - for COVID-19 severe or critically
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 deaths 1.10 [0.49, 2.45]< 1 0% 1 study (1/-) 40.8 % low not evaluable high crucial - clinical improvement 1.23 [0.87, 1.74]> 1 0% 1 study (1/-) 87.7 % low not evaluable high important - clinical improvement (14-day) 1.21 [0.64, 2.28]> 1 0% 1 study (1/-) 71.9 % low not evaluable high important - clinical improvement (28-day) 1.37 [0.79, 2.39]> 1 0% 1 study (1/-) 86.8 % low not evaluable high important - clinical improvement (7-day) 0.99 [0.18, 5.51]> 1 0% 1 study (1/-) 49.4 % low not evaluable high important - clinical improvement (time to event analysis only) 1.23 [0.87, 1.74]> 1 0% 1 study (1/-) 87.7 % low not evaluable high important - 00 AE leading to drug discontinuation 2.43 [0.79, 7.45]< 1 0% 1 study (1/-) 6.0 % low not evaluable high important - serious adverse events 0.64 [0.33, 1.23]< 1 0% 1 study (1/-) 91.0 % low not evaluable high important - deep vein thrombosis 0.50 [0.03, 8.10]< 1 0% 1 study (1/-) 68.5 % low not evaluable high non important - elevated liver enzymes 0.36 [0.13, 1.01]< 1 0% 1 study (1/-) 97.3 % low not evaluable high non important - hyperbilirubinemia 1.09 [0.42, 2.79]< 1 0% 1 study (1/-) 43.1 % low not evaluable high non important - pulmonary embolism 0.50 [0.03, 8.10]< 1 0% 1 study (1/-) 68.5 % low not evaluable high non important - renal impairment 1.01 [0.03, 30.33]< 1 0% 1 study (1/-) 49.9 % low not evaluable high non important -
LoD: level of demonstration (
